EULAR 2019: Mallinckrodt's Acthar Gel delivers in real-world setting

Mallinckrodt (NYSE: MNK) reported that all primary and secondary outcome measures were met in its Phase IV study of Acthar Gel (repository corticotropin injection) in persistently active rheumatoid arthritis (RA) patients previously treated with disease-modifying anti-rheumatic drugs and corticosteroids.

The results, presented at the EULAR congress, showed that 63% of patients with persistently active RA achieved low disease activity at week 12, with Acthar offering significant improvements on placebo in multiple measures.

Acthar Gel is US Food and Drug Administration-approved as adjunctive therapy for short-term administration in RA, including for juvenile patients.